Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study to Evaluate the Safety, Efficacy and Pharmacokinetics of SPR001 (Tildacerfont) in Children Aged 2 to 17 Years With Congenital Adrenal Hyperplasia (CAH)

NCT05128942 is registered in ClinicalTrials.gov with Spruce Biosciences as lead sponsor.

NCT NCT05128942
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05128942 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study to Evaluate the Safety, Efficacy and Pharmacokinetics of SPR001 (Tildacerfont) in Children Aged 2 to 17 Years With Congenital Adrenal Hyperplasia (CAH)
Lead sponsor
Spruce Biosciences
Phase
Phase 2
Overall status
Terminated
Start date
December 10, 2021
Completion date
January 31, 2025
Enrollment
67 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

21-ohd, congenital adrenal hyperplasia